Show simple item record

dc.contributor.authorCipriani, V
dc.contributor.authorPontikos, N
dc.contributor.authorArno, G
dc.contributor.authorSergouniotis, PI
dc.contributor.authorLenassi, E
dc.contributor.authorThawong, P
dc.contributor.authorDanis, D
dc.contributor.authorMichaelides, M
dc.contributor.authorWebster, AR
dc.contributor.authorMoore, AT
dc.contributor.authorRobinson, PN
dc.contributor.authorJacobsen, JO
dc.contributor.authorSmedley, D
dc.date.accessioned2020-11-11T14:53:19Z
dc.date.available2020-04-16
dc.date.available2020-11-11T14:53:19Z
dc.date.issued2020-04
dc.identifier.citationCipriani, V.; Pontikos, N.; Arno, G.; Sergouniotis, P.I.; Lenassi, E.; Thawong, P.; Danis, D.; Michaelides, M.; Webster, A.R.; Moore, A.T.; Robinson, P.N.; Jacobsen, J.O.; Smedley, D. An Improved Phenotype-Driven Tool for Rare Mendelian Variant Prioritization: Benchmarking Exomiser on Real Patient Whole-Exome Data. Genes 2020, 11, 460.en_US
dc.identifier.otherARTN 460
dc.identifier.urihttps://qmro.qmul.ac.uk/xmlui/handle/123456789/68197
dc.description.abstractNext-generation sequencing has revolutionized rare disease diagnostics, but many patients remain without a molecular diagnosis, particularly because many candidate variants usually survive despite strict filtering. Exomiser was launched in 2014 as a Java tool that performs an integrative analysis of patients’ sequencing data and their phenotypes encoded with Human Phenotype Ontology (HPO) terms. It prioritizes variants by leveraging information on variant frequency, predicted pathogenicity, and gene-phenotype associations derived from human diseases, model organisms, and protein–protein interactions. Early published releases of Exomiser were able to prioritize disease-causative variants as top candidates in up to 97% of simulated whole-exomes. The size of the tested real patient datasets published so far are very limited. Here, we present the latest Exomiser version 12.0.1 with many new features. We assessed the performance using a set of 134 whole-exomes from patients with a range of rare retinal diseases and known molecular diagnosis. Using default settings, Exomiser ranked the correct diagnosed variants as the top candidate in 74% of the dataset and top 5 in 94%; not using the patients’ HPO profiles (i.e., variant-only analysis) decreased the performance to 3% and 27%, respectively. In conclusion, Exomiser is an effective support tool for rare Mendelian phenotype-driven variant prioritizationen_US
dc.language.isoenen_US
dc.publisherMDPIen_US
dc.relation.ispartofGENES
dc.rightsCreative Commons Attribution (CC BY) license
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectwhole-exome sequencingen_US
dc.subjectwhole-genome sequencingen_US
dc.subjectrare diseaseen_US
dc.subjectvariant prioritizationen_US
dc.subjecthuman phenotype ontologyen_US
dc.subjectphenotypic similarityen_US
dc.subjectbioinformaticsen_US
dc.subjectinherited retinal diseaseen_US
dc.titleAn Improved Phenotype-Driven Tool for Rare Mendelian Variant Prioritization: Benchmarking Exomiser on Real Patient Whole-Exome Dataen_US
dc.typeArticleen_US
dc.rights.holder© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
dc.identifier.doi10.3390/genes11040460
pubs.author-urlhttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000537224600063&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6aen_US
pubs.issue4en_US
pubs.notesNot knownen_US
pubs.publication-statusPublisheden_US
pubs.volume11en_US
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Creative Commons Attribution (CC BY) license
Except where otherwise noted, this item's license is described as Creative Commons Attribution (CC BY) license